Int’l - Boehringer Ingelheim and Danish Meat Associations to fully settle vaccine case in Denmark
Published:September 8, 2006
Source :Boehringer Ingelheim Animal Health
Danish pig producers have today entered into a settlement with Boehringer Ingelheim Denmark A/S in a court case concerning the vaccination of Danish pig herds with a vaccine, which is used to prevent the dreaded pig disease Porcine Reproductive and Respiratory Syndrome (PRRS).
This settlement will close the case filed by Danish Meat Associations, a Danish farmer organisation.
Boehringer Ingelheim, the manufacturer of the vaccine, had first negotiations with the lawyer representing a group of 65 farmers last year and accepted settlement last week. Danish Meat Associations, representing claims for compensation of more than 140 farmers approached Boehringer Ingelheim shortly after. The company now announced that it has agreed to the settlement offer from Danish Meat Associations. Financial details were not disclosed.
“Our core business in Animal Health at Boehringer Ingelheim is to research, develop and market effective and safe vaccines. We hope that by agreeing to close this case, which does not mean that Boehringer Ingelheim would accept any allocation of blame for the damages, we are able to fully concentrate on our core business. Our products are intended to prevent farmers from experiencing losses caused by deadly animal diseases”, said Dr Joachim Hasenmaier, Head of Corporate Division Animal Health at Boehringer Ingelheim.
He added: “We believe in the mutual benefit of a long-term, stable relationship with farmers around the globe. With the decision to end this case in mutual agreement, we also hope to contribute to further enhance the farmers’ trust in the research based pharmaceutical industry, where true innovations come from to eventually help farmers keep their herds healthy.”
Boehringer Ingelheim is manufacturing and marketing Ingelvac® PRRS MLV, an approved vaccine with proven efficacy and safety to combat PRRS. Since its first launch, 350 million doses have been sold in more than 20 countries, where the vaccine is approved. Last year, Boehringer Ingelheim has been granted market authorisation in China and Thailand.
